Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study
Publication
, Conference
Mauro, M; Visotcky, A; Flynn, KE; Radich, JP; Yang, J; Oehler, VG; Cortes, JE; Kota, VK; Tantravahi, SK; Baim, A; Zhang, M-J; Hinman, A ...
Published in: Blood
November 15, 2022
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2022
Volume
140
Issue
Supplement 1
Start / End Page
6765 / 6766
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Mauro, M., Visotcky, A., Flynn, K. E., Radich, J. P., Yang, J., Oehler, V. G., … Sweet, K. (2022). Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study. In Blood (Vol. 140, pp. 6765–6766). American Society of Hematology. https://doi.org/10.1182/blood-2022-160138
Mauro, Michael, Alexis Visotcky, Kathryn E. Flynn, Jerald P. Radich, Jay Yang, Vivian G. Oehler, Jorge E. Cortes, et al. “Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study.” In Blood, 140:6765–66. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-160138.
Mauro M, Visotcky A, Flynn KE, Radich JP, Yang J, Oehler VG, et al. Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study. In: Blood. American Society of Hematology; 2022. p. 6765–6.
Mauro, Michael, et al. “Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 6765–66. Crossref, doi:10.1182/blood-2022-160138.
Mauro M, Visotcky A, Flynn KE, Radich JP, Yang J, Oehler VG, Cortes JE, Kota VK, Tantravahi SK, Baim A, Zhang M-J, Hinman A, Atallah EL, Sweet K. Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study. Blood. American Society of Hematology; 2022. p. 6765–6766.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2022
Volume
140
Issue
Supplement 1
Start / End Page
6765 / 6766
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology